Akari Therapeutics Plc - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Akari Therapeutics Plc on June 23, 2026, reporting events occurring on that date and the subsequent closing on June 26, 2026. The filing details an amendment to a previously disclosed securities purchase agreement regarding a private placement offering.
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, margin, or debt figures. The primary financial activity reported is the completion of a capital raise:
- Offering Structure: Sale of 1,470,588 unregistered American Depository Shares (ADSs) or prefunded warrants, plus Series H, I, and J warrants.
- Closing Schedule: Originally planned in three tranches (May 27, June 15, and July 15, 2026).
- Amended Closing: The Second and Third tranches were consolidated into a single "Combined Closing Date" on June 26, 2026.
- Shares Issued: 980,395 ADSs (or prefunded warrants) were issued on the Combined Closing Date.
Material Changes
The material change reported is the acceleration and consolidation of the capital raise closing schedule. The Company and Investors amended the Purchase Agreement to combine the originally scheduled June 15 and July 15 closings into one event on June 26, 2026. No other terms of the Purchase Agreement were altered.
Outlook, Risks, and Contingencies
Contingency: The delivery of the Series H, Series I, and Series J warrants is contingent upon receiving shareholder approval at the Company's annual general meeting scheduled for June 30, 2026.
Management Commentary: The filing contains no forward-looking guidance, risk factors, or management commentary beyond the factual description of the agreement amendment and closing.
Investor Verification Checklist
- Verify the outcome of the shareholder vote at the annual general meeting on June 30, 2026, to confirm the issuance of the Series Warrants.
- Review the full text of the Amendment to the Securities Purchase Agreement (Exhibit 10.1) for any non-standard terms.
- Confirm the total gross proceeds received from the First Closing (May 27) and the Combined Closing (June 26) in subsequent financial filings, as specific dollar amounts are not listed in this 8-K.